CanopyisEnterpriseAIforOncology
Canopy is Enterprise AI for Oncology
For oncology, by oncology.
Rooted in oncology expertise, designed for oncology practices.
AI that works with you, not instead of you.
Extend your capabilities with solutions that leverage your existing workflows.
Built for how oncology works
Trusted in the most important moments.
Built to strengthen every step that drives the quality of care.
Practical solutions – from the front door to the back office
Canopy connects and automates workflows across all patient services.
Call Center
Leverage smart workflow tools and supplementary AI agents to support patients 24/7, including after hours and busy Mondays.
Treatment Management
Keep a pulse on each patient's symptoms between visits, with decision support that prioritizes issues so clinicians can focus on patients who need them most.
Front Office
Simplify every step before and between visits, from scheduling to refills, so nothing gets missed.
Pharmacy
Track and improve adherence across patients while digitally streamlining refills.
New Patient
Centralize referrals and coordination across channels with AI—getting more new patients seen.
Dr. Debra Patt
Executive Vice President of Public Policy and Strategy, Texas Oncology
Source: Internal analysis of practice use of Canopy software
Dr. Jeff Vacirca
CEO, New York Cancer & Blood Specialists, and Co-Founder, OneOncology
Source: Kolodziej et al., J Clin Oncol. 2022;40(16_suppl):1508.
Jeff Hunnicutt
CEO, Highlands Oncology
Source: Internal analysis of practice use of Canopy software
Proven in oncology practices, validated by data
Selected findings from peer-reviewed studies
RESULT
Up to 45% of patients stayed on treatment at 3 months with Canopy ePRO monitoring
Time on treatment is prolonged in patients utilizing an ePRO based digital symptom monitoring platform in the community setting.
RESULT
Canopy ePRO surfaced more AEs in near real-time for chemo and bispecific regimens
Electronic Patient-Reported Outcome (ePRO) Symptom Monitoring for Relapsed/Refractory Multiple Myeloma in Community Settings, Focusing on Bispecific Antibody Therapy.
RESULT
In aMel, pembrolizumab alone was tied to fewer symptoms than nivolumab and ipilimumab
Electronic patient-reported outcomes (ePRO) in patients with advanced melanoma receiving immune checkpoint inhibitors: Insights from the Canopy ePRO system.